Drug Topics
NOVEMBER 5, 2023
Authors of a platinum-ranked poster presented at AMCP Nexus 2023 suggested that the burden of increased spending on specialty medications varies by race and wage among employees with employer-sponsored health insurance.
Pharmacy Times
NOVEMBER 5, 2023
Other than dialysis, Shah notes that patients with kidney disease who are pregnant can receive either nifedipine or labetalol to control blood pressure.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Healthcare
NOVEMBER 5, 2023
Family physicians utilizing value-based payment (VBP) models reported burnout relief in a new study from EHR com | The study found that higher capitation rates combined with greater overall percentage of revenue from capitation resulted in the biggest reduction in physician burnout.
Pharmacy Times
NOVEMBER 5, 2023
Deep-rooted discrimination and stigma can contribute to stressors that worsen disease progression and access to care, according to experts.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Healthcare
NOVEMBER 5, 2023
Healthcare is becoming increasingly unaffordable for many consumers, and rising medical costs often limit patients' access to much-needed care. | The company launched a new software suite, called Affordability Navigator, to connect consumers with outside funding sources and self-service tools. It also integrates Medicaid enrollment into the billing experience.
Pharmacy Times
NOVEMBER 5, 2023
Nickolas also describes how the use of novel imaging technologies, microRNA, and transcriptomics help experts better understand underlying pathogenesis of ROD.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
NOVEMBER 5, 2023
Walmart Health is making a move to better coordinate patient care between its health centers in Florida and a major health system. | Walmart Health is making a move to better coordinate patient care between its health centers in Florida and a major health system.
Med Ed 101
NOVEMBER 5, 2023
We are offering a ONE TIME ONLY discount of $100 on the 1 year BCPS all-access pass and I also have 10 Free Audible books to give away. ONLY the first 10 purchases will get the Free Audible version of my Drug Interaction Book (10+ hours of bonus content) as I only have a limited […] The post One Time ONLY! $100 Discount and Free Audible Book – BCPS Study Materials appeared first on Med Ed 101.
Fierce Healthcare
NOVEMBER 5, 2023
Viome Life Sciences has snatched up Naring Health to build out its personalized nutrition offerings and further its goal to bring at-home diagnostics to the masses. | Viome will use Naring Health's clinical and molecular data to expand and improve its personalized medicine offerings.
Pharmaceutical Technology
NOVEMBER 5, 2023
Two more medtech darlings have closed their doors this week, signalling an end to the funding rush of Covid.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Dr. Jamie Hardy: The Lifestyle Pharmacist
NOVEMBER 5, 2023
Our team is committed to helping you achieve total wellness. That’s why we have carefully curated two incredible bundles that are designed to support your overall well-being plus support you on your weight management journey. In case you have not heard about them, let me introduce you to the Totally FAB Bundle for complete wellness and the Get Snatched Bundle for effective weight management.
The FDA Law Blog
NOVEMBER 5, 2023
The 14th Asia Pacific Symposium on Cochlear Implant and Related Sciences is poised to captivate the global scientific community from November 8-11, 2023, as it convenes in Seoul, Korea. This prestigious four-day conference promises to deliver a wealth of cutting-edge insights, featuring presentations by eminent scientists and clinicians, all unified under the thought-provoking theme, “Towards Better Speech Perception and Beyond.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myeloproliferative Disorders.
Dr. Jamie Hardy: The Lifestyle Pharmacist
NOVEMBER 5, 2023
At Be Fab, we are committed to helping you achieve total wellness and reach your weight management goals. That’s why we have carefully curated two incredible bundles that are designed to support your overall well-being and help you on your weight management journey. Introducing the Totally FAB Bundle for complete wellness and the Get Snatched Bundle for effective weight management.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Technology
NOVEMBER 5, 2023
ABP-671 is under clinical development by Jiangsu Atom Bioscience and Pharmaceutical and currently in Phase II for Hyperuricemia.
The Guardian - Pharmaceutical Industry
NOVEMBER 5, 2023
Exclusive: Regulator extends part suspension of licence to July 2024 after IT blunder led to incorrect dosage of cancer treatment A private health company paid millions by the NHS has failed to fix safety defects that led to the death of a cancer patient, the Guardian can reveal. Three patients were hospitalised and a fourth died when they were given the wrong doses of a powerful chemotherapy drug after a catastrophic IT failure at the medicine manufacturing unit of Sciensus in April this year.
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-100 is under clinical development by Alto Neuroscience and currently in Phase II for Post-Traumatic Stress Disorder (PTSD).
Roots Analysis
NOVEMBER 5, 2023
Cancer is the second leading cause of death globally, and the increasing global incidence of cancer is becoming a critical health challenge. According to WHO, approximately 16.3 million cancer related deaths are likely to occur by 2040. In order to address the growing cancer burden, numerous cancer research organizations are actively adopting innovative strategies and patient-centered approaches for early cancer detection and treatment of cancer.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmaceutical Technology
NOVEMBER 5, 2023
(Favezelimab + pembrolizumab) is under clinical development by Merck and currently in Phase II for Bladder Cancer.
Pharmaceutical Technology
NOVEMBER 5, 2023
(Favezelimab + pembrolizumab) is under clinical development by Merck and currently in Phase II for Melanoma.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Lymphoma.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Solid Tumor.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myelodysplastic Syndrome.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Myeloproliferative Disorders.
Pharmaceutical Technology
NOVEMBER 5, 2023
BGB-16673 is under clinical development by BeiGene and currently in Phase II for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-300 is under clinical development by Alto Neuroscience and currently in Phase II for Major Depressive Disorder.
Pharmaceutical Technology
NOVEMBER 5, 2023
ALTO-100 is under clinical development by Alto Neuroscience and currently in Phase II for Post-Traumatic Stress Disorder (PTSD).
Pharmaceutical Technology
NOVEMBER 5, 2023
(Favezelimab + pembrolizumab) is under clinical development by Merck and currently in Phase II for Bladder Cancer.
Pharmaceutical Technology
NOVEMBER 5, 2023
(Favezelimab + pembrolizumab) is under clinical development by Merck and currently in Phase II for Melanoma.
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia).
Pharmaceutical Technology
NOVEMBER 5, 2023
KT-253 is under clinical development by Kymera Therapeutics and currently in Phase I for Lymphoma.
Expert insights. Personalized for you.
190 
Let's personalize your content